No abstract available
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage
-
Administration, Oral
-
Anti-Ulcer Agents / administration & dosage
-
Antimetabolites, Antineoplastic / blood
-
Antimetabolites, Antineoplastic / pharmacokinetics
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Area Under Curve
-
Biological Availability
-
Clinical Trials as Topic
-
Dihydrouracil Dehydrogenase (NADP) / blood
-
Drug Combinations
-
Fasting
-
Fluorouracil / analogs & derivatives
-
Fluorouracil / metabolism
-
Food
-
Gastric Acidity Determination
-
Half-Life
-
Humans
-
Hydrogen-Ion Concentration
-
Oxonic Acid / blood
-
Oxonic Acid / metabolism
-
Oxonic Acid / pharmacokinetics*
-
Oxonic Acid / therapeutic use*
-
Pantoprazole
-
Pyridines / metabolism
-
Pyridines / pharmacokinetics
-
Pyridines / therapeutic use
-
Tegafur / blood
-
Tegafur / metabolism
-
Tegafur / pharmacokinetics*
-
Tegafur / therapeutic use*
-
Triazines / metabolism
-
Uracil / analogs & derivatives
-
Uracil / metabolism
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / metabolism
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Anti-Ulcer Agents
-
Antimetabolites, Antineoplastic
-
Drug Combinations
-
Pyridines
-
Triazines
-
dihydrouracil
-
beta-Alanine
-
S 1 (combination)
-
Tegafur
-
alpha-fluoro-beta-alanine
-
potassium oxonate
-
Uracil
-
Oxonic Acid
-
5-fluorodihydrouracil
-
Pantoprazole
-
Dihydrouracil Dehydrogenase (NADP)
-
cyanuric acid
-
Fluorouracil
-
gimeracil